A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma - Wikidata - awgldk - TriplyDB

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma

http://www.wikidata.org/entity/Q35285695

about

New viruses for cancer therapy: meeting clinical needs Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses Going viral: a review of replication-selective oncolytic adenoviruses The evolution of poxvirus vaccines Role of microRNAs in hepatocellular carcinoma: a clinical perspective Trial Watch:: Oncolytic viruses for cancer therapy Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1 Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Oncolytic Poxviruses.Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma.Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes Trial watch: Oncolytic viruses for cancer therapy Myxoma virus therapy for human embryonal rhabdomyosarcoma in a nude mouse model.Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo.Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.Progress of oncolytic viruses in sarcomas.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Oncolytic vaccines.Immunotherapeutic potential of oncolytic vaccinia virus.Oncolytic virus immunotherapy for melanoma.Treatment of Liver Cancer.T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.Talimogene laherparepvec in the treatment of melanoma.

P2860

Q24567699-794B8BD1-8DB4-4C59-8A65-2EEBB19377AF Q26739777-A148571B-40CD-42FC-B39B-1929102982E3 Q26752807-F52E03FB-6053-4B5A-9A71-4831E4DD6021 Q26797520-E1093DEF-BBF4-4D9B-B220-42AFE56A8B78 Q26995905-8599A5F8-6B63-4CF2-9616-F796C098EB48 Q27014034-14CB13E4-CB7C-4EB7-86A2-372070C550A3 Q27021951-72D077A4-D045-4F12-AE6D-3925BF8B1F25 Q28067023-53A8FDB7-7A0A-4BC8-8C47-9F68AB32F3CA Q28071998-4DD4FC23-5FDA-4A4E-AA68-BE27F3C54920 Q28483092-1236F949-0085-4C58-8914-4AFD23BDFE75 Q33579883-C2DF118F-F736-48F2-A8F4-1429D8EE1FF9 Q33625843-0182BFCB-1A72-485F-892E-7C5826497778 Q34020594-C964F5C4-352E-499A-96A6-504F062497DC Q34327051-C4604899-30D5-45AE-8F18-1278424DBF44 Q35224606-08C227A6-6B4A-4FFC-A98A-5C3A1DDC1A2C Q35234349-B065EFE7-4692-45A7-B3ED-0EE86098DE1D Q35809324-0F339BB8-6447-4616-A3F7-60C6338E9F83 Q36028552-F25E6316-B753-40F0-921A-D36B9EDFD517 Q36102807-7773CA91-478F-43EA-BD50-2D7DE680DE85 Q36391900-53B05E48-DDE3-4A30-9D94-AD080FFBE42D Q36659289-8B4A2494-8B4F-4A4A-8BE7-7CD2831DCD73 Q36664201-01DFEF2A-4FD2-4015-BA06-E1CEAE26D30F Q36664268-B0F3DD92-B306-4AD1-8FCA-A45D46D192C9 Q36738884-5FB2AC7F-7FD1-48C9-9050-88EFF20446C5 Q36756690-43456DEE-30AA-4AB5-955E-786BFB135B38 Q36911654-20FA72E4-23E2-4D2A-A7E4-628BD6218871 Q37028023-A3E27A03-BF8B-4568-B8E1-0D4FEB615272 Q37200546-B9D6FBCC-F168-4612-85BE-3E5CA61D7E84 Q37641458-01693A31-9389-48E6-9667-32F2554383B1 Q37687542-CDA44F77-55B1-4579-985A-8F58EA2236BD Q37728885-918E9802-78CE-4C87-AC2D-130E0D190DD9 Q37982449-B2F22252-EB9E-4510-A6C8-4BAA91B7DF8D Q38025696-961100BE-151B-4B7F-8246-72818BCE61D0 Q38033591-DCE21CBD-2DD1-4123-8B43-7DBA05E67735 Q38152474-B5F22119-E231-4682-886A-F5A7035EBF68 Q38225561-EABAF60B-0A70-498B-A34C-1228AB0E9D4C Q38380394-829CB0E3-71FC-4B36-BF72-E3E287EF740F Q38549768-47E337BC-AD6F-4507-A111-DC9EFB56802F Q38648630-C1AE419B-EE6D-4C3D-9C28-31613A71D7F0 Q38656524-38B21FAD-4DFA-4049-B975-042C3F08A805

P2860

A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma

http://www.wikidata.org/entity/Q35285695

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A mechanistic proof-of-concept ...... ients with metastatic melanoma

@ast

A mechanistic proof-of-concept ...... ients with metastatic melanoma

@en

type

label

A mechanistic proof-of-concept ...... ients with metastatic melanoma

@ast

A mechanistic proof-of-concept ...... ients with metastatic melanoma

@en

prefLabel

A mechanistic proof-of-concept ...... ients with metastatic melanoma

@ast

A mechanistic proof-of-concept ...... ients with metastatic melanoma

@en

P1433

Q35285695-A83C40AB-3084-42E2-A707-8F3A6A5CB544

P1476

Q35285695-C831A19E-292B-4CA1-A6C2-9C55C1A059B5

P2093

Q35285695-129770A9-5C70-4C5B-9C40-BEB0BF39498B

Q35285695-19B7961D-6555-4FA4-B3F2-34F8F6269FC0

Q35285695-2706C6C6-C730-4F51-BC80-CA312E156F62

Q35285695-3234DBAB-9929-46E0-B63B-607AE7BB7816

Q35285695-40182E91-9C87-43BC-8992-0FE91EC9A5A0

Q35285695-52C6CA36-C418-4121-99D5-6A0CF4863D55

Q35285695-5DA63981-E85A-41F4-9020-191F0123AE62

Q35285695-6E9D37C4-3FA5-44E0-B8FC-399FEA6275BE

Q35285695-9024585B-C751-4732-B0C4-E1DF573E76B6

Q35285695-B39D598A-7CD2-435A-A893-0581998EE87D

P2860

Q35285695-026CD068-0A49-4DB0-A70D-897E6D56FB3F

Q35285695-0A1EFF52-84E1-47FE-A041-A49DACDADC92

Q35285695-11EF785C-51F0-4DBA-B214-994FE3689DF2

Q35285695-265959CE-EC64-40F1-99D2-35F27E177FCF

Q35285695-3BBCFAF5-6EB2-4C88-9780-780B540FDCA7

Q35285695-3D2ADFB4-7D3F-4D61-B963-AFA3F554B19A

Q35285695-442E0D97-37EA-49CA-A726-D318FE3D04F1

Q35285695-4BEFC45D-1DA1-4D50-A4EE-D4305C66504A

Q35285695-4C9C0AC3-06B4-4F49-920B-3F021072DBE6

Q35285695-6DD1BC41-ABFB-4644-9CA0-CF1688580446

P304

Q35285695-7BFEB6D1-8E3E-48AB-B513-4FEE78016995

P31

Q35285695-7DCE3432-FA9D-4F73-8586-0B81CF75FD62

P356

Q35285695-E374FF22-1115-4D1E-A83A-C08B8C7F8125

P433

Q35285695-7080FB88-0F43-4647-8901-FBC4033154ED

P478

Q35285695-562E1732-CA8A-42BB-B496-FF33641423F7

P50

Q35285695-69A71872-60E2-47EB-A67E-F22F5E308712

P577

Q35285695-8EAD5FC8-12B1-48BD-BE21-05CE82B36299

P5875

Q35285695-9F4EDBBA-388C-45BE-B6BD-CB1698AEAD27

P698

Q35285695-0F56B719-3FAA-4338-A0DF-64C28795E62A

P921

Q35285695-FA6351E4-61C4-4250-85BD-F92411356A43

P932

Q35285695-0E16263F-06C5-4FF5-B91C-2913FFD6C2B6

P356

P1433

Molecular Therapy

P1476

A mechanistic proof-of-concept ...... ients with metastatic melanoma

@en

P2093

Anne Moon

http://www.w3.org/2001/XMLSchema#string

Antoni Ribas

http://www.w3.org/2001/XMLSchema#string

Caroline J Breitbach

http://www.w3.org/2001/XMLSchema#string

David H Kirn

http://www.w3.org/2001/XMLSchema#string

James Burke

http://www.w3.org/2001/XMLSchema#string

Jean-Simon Diallo

http://www.w3.org/2001/XMLSchema#string

Joe Stephenson

http://www.w3.org/2001/XMLSchema#string

Kelley Parato

http://www.w3.org/2001/XMLSchema#string

Manijeh Daneshmand

http://www.w3.org/2001/XMLSchema#string

Naomi De Silva

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

P304

1913-1922

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2011.132

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51505133

http://www.w3.org/2001/XMLSchema#string

P698

21772252

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3188739

http://www.w3.org/2001/XMLSchema#string